Cargando…
Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients
BACKGROUND AIMS. TissueGene-C (TG-C) represents a cell-mediated gene therapy for localized delivery of allogeneic chondrocytes expressing transforming growth factor (TGF)-β1 directly to the damaged knee joint. Untransduced human chondrocytes (hChonJ cells) have also been incorporated into the TG-C p...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Informa Healthcare
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3793276/ https://www.ncbi.nlm.nih.gov/pubmed/22242865 http://dx.doi.org/10.3109/14653249.2011.629645 |
_version_ | 1782286941251698688 |
---|---|
author | Ha, Chul-Won Noh, Moon Jong Choi, Kyoung Baek Lee, Kwan Hee |
author_facet | Ha, Chul-Won Noh, Moon Jong Choi, Kyoung Baek Lee, Kwan Hee |
author_sort | Ha, Chul-Won |
collection | PubMed |
description | BACKGROUND AIMS. TissueGene-C (TG-C) represents a cell-mediated gene therapy for localized delivery of allogeneic chondrocytes expressing transforming growth factor (TGF)-β1 directly to the damaged knee joint. Untransduced human chondrocytes (hChonJ cells) have also been incorporated into the TG-C product at a 3:1 ratio with TGF-β1-expressing chondrocytes (hChonJb#7) in order to help fill in the defect and as target cells for the actions of the expressed TGF-β1. METHODS. A phase I dose-escalating clinical trial was performed to evaluate the safety and biologic activity of TG-C in patients with advanced osteoarthritis of the knee joint (full thickness cartilage defect) that was refractory to existing non-operative therapies. Following a single intra-articular injection into the joint space of the damaged knee, patients were monitored for safety, and an evaluation was performed to assess the pharmacokinetics and biologic activity of TG-C. RESULTS. There were no treatment-related serious adverse events. Swelling, effusion and minor localized reactions such as warming sensation or itching were observed in a dose-dependent manner at the injection site. Knee evaluation scores seemed to indicate a dose-dependent trend toward efficacy; however, patient numbers were not sufficient to determine statistical significance. CONCLUSIONS. Overall, there were no significant safety issues related to the administration of TG-C, with only some minor injection site reactions observed. Additionally, knee scoring analyzes indicated a possibility that TG-C may contribute to improvement of arthritic symptoms. More study is warranted to evaluate further the safety and determine the potential efficacy of TG-C. |
format | Online Article Text |
id | pubmed-3793276 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Informa Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-37932762013-10-11 Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients Ha, Chul-Won Noh, Moon Jong Choi, Kyoung Baek Lee, Kwan Hee Cytotherapy Original Article BACKGROUND AIMS. TissueGene-C (TG-C) represents a cell-mediated gene therapy for localized delivery of allogeneic chondrocytes expressing transforming growth factor (TGF)-β1 directly to the damaged knee joint. Untransduced human chondrocytes (hChonJ cells) have also been incorporated into the TG-C product at a 3:1 ratio with TGF-β1-expressing chondrocytes (hChonJb#7) in order to help fill in the defect and as target cells for the actions of the expressed TGF-β1. METHODS. A phase I dose-escalating clinical trial was performed to evaluate the safety and biologic activity of TG-C in patients with advanced osteoarthritis of the knee joint (full thickness cartilage defect) that was refractory to existing non-operative therapies. Following a single intra-articular injection into the joint space of the damaged knee, patients were monitored for safety, and an evaluation was performed to assess the pharmacokinetics and biologic activity of TG-C. RESULTS. There were no treatment-related serious adverse events. Swelling, effusion and minor localized reactions such as warming sensation or itching were observed in a dose-dependent manner at the injection site. Knee evaluation scores seemed to indicate a dose-dependent trend toward efficacy; however, patient numbers were not sufficient to determine statistical significance. CONCLUSIONS. Overall, there were no significant safety issues related to the administration of TG-C, with only some minor injection site reactions observed. Additionally, knee scoring analyzes indicated a possibility that TG-C may contribute to improvement of arthritic symptoms. More study is warranted to evaluate further the safety and determine the potential efficacy of TG-C. Informa Healthcare 2012-02 2012-01-12 /pmc/articles/PMC3793276/ /pubmed/22242865 http://dx.doi.org/10.3109/14653249.2011.629645 Text en © 2012 Informa Healthcare http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the source is credited. |
spellingShingle | Original Article Ha, Chul-Won Noh, Moon Jong Choi, Kyoung Baek Lee, Kwan Hee Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients |
title | Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients |
title_full | Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients |
title_fullStr | Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients |
title_full_unstemmed | Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients |
title_short | Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients |
title_sort | initial phase i safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3793276/ https://www.ncbi.nlm.nih.gov/pubmed/22242865 http://dx.doi.org/10.3109/14653249.2011.629645 |
work_keys_str_mv | AT hachulwon initialphaseisafetyofretrovirallytransducedhumanchondrocytesexpressingtransforminggrowthfactorbeta1indegenerativearthritispatients AT nohmoonjong initialphaseisafetyofretrovirallytransducedhumanchondrocytesexpressingtransforminggrowthfactorbeta1indegenerativearthritispatients AT choikyoungbaek initialphaseisafetyofretrovirallytransducedhumanchondrocytesexpressingtransforminggrowthfactorbeta1indegenerativearthritispatients AT leekwanhee initialphaseisafetyofretrovirallytransducedhumanchondrocytesexpressingtransforminggrowthfactorbeta1indegenerativearthritispatients |